All News

Patients on Emgality experienced an average of 8.7 fewer weekly episodic cluster headaches.

Training programs reflect the changing practice of pharmacies.

Improve your counseling skills to make the most of medication therapy management in your community pharmacy.

The agreement will bring real-world data to cancer treatment development.

After several manufacturing and sterility issues, a permanent injunction has been issued against a Pharm D Solutions, LLC.

The action by the U.S. Attorney's Office is the latest in legal and policy maneuvers aimed at ending the opioid epidemic.

Earn up to 19.25 hours of CE.

This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes.

New indication adds to the oral antipsychotic’s portfolio of conditions.

Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy

The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.

Overestimating the bleeding risk of anticoagulants may lead to poor compliance.

Vitamin D analog foam indicated for topical treatment of plaque psoriasis in teens.

Deciding which sunscreen to apply has become a complicated business.

Oral solution now approved for adults and pediatric patients.

Update: now available from three manufacturers. 

Specialty pharmacy has reached an “inflection point” with the power to change the entire industry model.

Nayzilam is a benzodiazepine antiepileptic nasal spray.

North Carolina working to expand the number of vaccines pharmacists can administer.

Medical researchers and physicists are collaborating on oral vaccine research.

Both pharmacy groups state that rule should have addressed DIR fees.

Studies indicate a lack of deprescribing is causing physical and fiscal pain to patients. 

Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.

Venetoclax, a BCL-2 inhibitor first approved in 2016, is now indicated for chronic lymphocytic leukemia and small lymphocytic lymphoma.

Pete Kreckel discusses how he is always working to improve the workflow in his pharmacy. 

Xellia Pharmaceuticals will manufacture essential antibiotics for Civica Rx.

Approval marks the first anti-PD-L1 therapy combination for RCC.

With tight margins, DIR fees, generic effective rate fees, and the delay in receiving third-party reimbursements, it’s easy to find yourself faced with cash flow pressures.